|
|
 |
|
Viewing report
|
|
|
|
Orphan Drug Strategies
Datamonitor, Oct 2009, Pages: 75
With the pharmaceutical industry reducing its focus on the primary care blockbuster model, Big Pharma is now looking towards the development and commercialization of more niche, high value, often biologic therapies, for the treatment of smaller patient populations.
Scope
- Provides an overview of orphan drugs, including drivers and resistors of investing in this niche market
- Examines orphan drug developmental and approval trends
- Analyzes Big Pharma's attraction towards orphan drugs, supplemented with future forecast analysis
- Assesses the future size and growth of the orphan drugs market
Highlights of this title
Few markets have implemented robust orphan drug policies with the exception of the US, Europe, Japan, Australia and Singapore. Nevertheless, a number of key emerging markets have instigated partial orphan drug policies which are anticipated to be strengthened in the near future.
With increasing cost pressures facing payers, combined with the growing number of orphan drugs now on the market and in development, measures aimed at reducing costs can be expected by shifting payment onto the patient or even the pharma companies themselves through risk-sharing agreements.
Oncology is the most frequently investigated therapy area, with nearly half of all pipeline orphan drugs designated for such indications. However, with the availability of marketed products for a number of the most frequently targeted orphan indications, competition in these areas is set to grow.
Key reasons to purchase this title
- Gain insight into the challenges companies face when developing and commercializing orphan drugs.
- Examine which are the most popular orphan indications, and the most dominant orphan drug players in the market.
- Identify strategies to maximize the commercial opportunities of orphan drugs through both revenue expansion and protection.
Customers who bought this item also bought
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2011 Edition
Orphan Drug Markets in Europe: Key Developments and the Strategies of Major Pharmaceutical Companies
Opportunities in Orphan Drugs: Strategies for developing maximum returns from niche indications
Orphan Drug Trends 2011
Orphan Drugs: Strategic Approaches for the Industry
Clinical Trial Recruitment in Orphan Diseases - Patient Numbers in Ovarian Cancer Trials Exceed Other Orphan Diseases in Oncology
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
Drug Repositioning: New Technologies, Business Models & Strategies for Successful Development
Personalized Medicine - Scientific and Commercial Aspects
The Future of Orphan Disease Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement
|
|
|
|
